Bank of America Corp DE Lowers Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Bank of America Corp DE reduced its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 72.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 215,999 shares of the company’s stock after selling 559,537 shares during the quarter. Bank of America Corp DE’s holdings in Zentalis Pharmaceuticals were worth $654,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the stock. Prudential Financial Inc. bought a new position in Zentalis Pharmaceuticals in the fourth quarter worth approximately $39,000. Cerity Partners LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at approximately $40,000. Ieq Capital LLC purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $46,000. Oxford Asset Management LLP bought a new position in Zentalis Pharmaceuticals in the 4th quarter worth about $52,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Zentalis Pharmaceuticals during the 4th quarter worth about $53,000.

Zentalis Pharmaceuticals Stock Down 2.0%

Shares of Zentalis Pharmaceuticals stock opened at $1.49 on Tuesday. The company has a market capitalization of $107.21 million, a P/E ratio of -0.60 and a beta of 1.61. The company has a 50 day moving average of $1.29 and a 200 day moving average of $2.07. Zentalis Pharmaceuticals, Inc. has a 52-week low of $1.01 and a 52-week high of $10.68.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts’ consensus estimates of ($0.67). As a group, research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on ZNTL. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Wedbush reiterated a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.24.

Insiders Place Their Bets

In related news, Director Scott Dunseth Myers acquired 21,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the purchase, the director now directly owns 281,192 shares of the company’s stock, valued at approximately $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is owned by insiders.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.